Brigatinib (AP26113)
-
Catalog number9675-25
-
PricePlease ask
-
Size25 mg
-
-
Alternative_name(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
-
DescriptionBrigatinib is a highly potent and selective ALK (anaplastic lymphoma kinase) inhibitor. Potentially useful for the treatment of non-small cell lung cancer (NSCLC).
-
CAS Number1197953-54-0
-
Structure AvailableYes
-
Salt FormNo
-
Molecular FormulaC₂₉H₃₉ClN₇O₂P
-
Molecular Weight584.09
-
Cell PermeableYes
-
Purity≥98% by HPLC
-
SolubilitiesDMSO (>15 mg/ml)
-
HandlingProtect from air and light
-
Tag LineA highly potent and selective ALK (anaplastic lymphoma kinase) inhibitor
-
Storage Condition-20°C
-
Shipping Conditiongel pack
-
Shelf Life36 months
-
PubChem CID68165256
-
SMILESCN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
-
InChiInChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
-
InChi KeyAILRADAXUVEEIR-UHFFFAOYSA-N
-
MSDS AvailableYes
-
Gene target
-
Short nameBrigatinib (AP26113)
-
Alternative nameBrigatinib (AP26113)
-